Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytokinetics, Incorporated (CYTK) SEC filings page on Stock Titan brings together the company’s public reports filed with the U.S. Securities and Exchange Commission. Cytokinetics is a Nasdaq-listed specialty cardiovascular biopharmaceutical company focused on muscle biology and diseases of cardiac muscle dysfunction, and its filings provide detailed information about its operations, capital structure and regulatory progress.
Recent Form 8-K current reports from Cytokinetics include disclosures about regulatory milestones for MYQORZO (aficamten), such as a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for symptomatic obstructive hypertrophic cardiomyopathy. Other 8-K filings describe financial results, the issuance of convertible senior notes due 2031, planned draws under a development funding loan agreement and executive appointments and compensation arrangements.
Investors reviewing CYTK filings can also track information about the company’s listing on The Nasdaq Global Select Market, its equity incentive plans, inducement grants under Nasdaq Listing Rule 5635(c)(4) and its use of proceeds from capital raises to support the potential commercial launch of aficamten and the advancement of its development pipeline. Additional SEC documents, such as annual and quarterly reports when available, typically include discussions of clinical programs in hypertrophic cardiomyopathy and heart failure, risk factors and financial statements.
On Stock Titan, these SEC filings are updated as new documents are released on EDGAR, and AI-powered tools can help summarize key points from lengthy reports so readers can more quickly understand the context and implications of Cytokinetics’ regulatory and financial disclosures.
CYTK Form 3 — initial statement by Director James M. Daly This filing reports that James M. Daly, listed as a director of Cytokinetics, Inc., filed an initial Form 3 dated 08/19/2025 and reports no securities beneficially owned in the issuer. The form was signed by an attorney-in-fact on Mr. Daly’s behalf.
Cytokinetics, Incorporated reported that its Board of Directors appointed James M. Daly as a Class III director effective August 19, 2025, with a term running through the company’s 2028 annual stockholders’ meeting. He will also serve on the Board’s Compliance Committee, and the Board has determined he is independent under SEC rules, Nasdaq standards and the company’s governance guidelines. The company states there are no related-party transactions requiring disclosure.
Mr. Daly will receive standard non-employee director compensation, including a $50,000 annual cash retainer for Board service and $7,500 annually for Compliance Committee service, both pro-rated for partial periods. He is also eligible for an annual equity award of restricted stock units and stock options with a combined grant date fair value of $440,000. In addition, on the effective date he received an initial stock option to purchase 27,450 shares, valued at $700,000, vesting monthly over three years, subject to continued Board service, and the company entered into its standard indemnification agreement with him.
Insider transactions by Dr. Malik Fady Ibraham, EVP Research & Development of Cytokinetics (CYTK), are reported on Form 4. On 08/19/2025 he exercised 2,000 non‑qualified stock options at an exercise price of $10.60 and concurrently sold 2,000 shares at $38.31. After these transactions he beneficially owned 140,610 shares. The filing shows 9,105 option shares remaining exercisable from the option series.
Insider transaction summary for CYTK: The Form 4 shows Robert I. Blum, President & CEO and a director of Cytokinetics Inc. (CYTK), reported a sale of 5,000 shares of the issuer's common stock on 08/15/2025 at a price of $38.42 per share. After the reported sale, Mr. Blum is recorded as directly owning 383,108 shares. The filing also discloses indirect holdings of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.
The Form 4 was filed by one reporting person and indicates the transaction may have been made pursuant to a written plan under Rule 10b5-1. The filing is signed by an attorney-in-fact for Mr. Blum on 08/15/2025.
Cytokinetics (CYTK) Q2-25 10-Q highlights: Revenue jumped to $66.8 m (Q2-24: $0.3 m) and $68.3 m for H1, driven by the Bayer Japan license (one-time $52.4 m recognition) and two €5 m milestones. Collaboration revenue remains modest. Operating loss narrowed to $111.5 m (-14% YoY), but six-month operating loss widened to $335.5 m. Net loss was $134.4 m for the quarter (-$1.12/sh) and $295.7 m YTD.
Balance sheet & liquidity: Cash, cash equivalents and investments total $1.0 bn, down from $1.2 bn at FY-24. Quarterly cash burn from operations was $259.9 m. Total liabilities rose to $1.59 bn (incl. $554 m convertible notes and $489 m revenue-participation liabilities) producing a stockholders’ deficit of $368.7 m. Additional $75 m was drawn on Royalty Pharma Tranche 4 in April; Tranche 5 ($100 m) remains available through Nov-25.
Pipeline/regulatory: NDA for aficamten in obstructive HCM accepted; PDUFA target date 26 Dec 2025. Phase 3 programs in non-obstructive HCM and pediatric HCM progressing. Omecamtiv mecarbil Greater China license terminated; rights reverted to CYTK. Cash runway expected to cover at least 12 months; management anticipates continued losses until commercial launch.